Dr. Awad Taj El-Din: Support and directives from President Sisi to localize modern pharmaceutical industries
Dr. Mohamed Awad Taj El-Din, Advisor to the President of the Republic for Health and Prevention Affairs, said that there is support and directives from President Abdel Fattah El-Sisi to work on the localization of modern pharmaceutical industries, especially oncology drugs and biological drugs, and to cooperate with international companies and institutions with a reputation, great experience, and innovative and manufacturing capabilities.
This came in a speech by Dr. Awad Taj El-Din, today, during the signing of a cooperation agreement between “Bayer” and… German company “Mina Pharm” To localize the pharmaceutical industry in the field of women’s health, in the presence of Dr. Khaled Abdel Ghaffar, Deputy Prime Minister and Minister of Health and Population, and Dr. Ali Al-Ghamrawi, Chairman of the Egyptian Pharmaceutical Authority, on the sidelines of the activities of the second day of the third edition of the World Conference on Population, Health and Human Development.
Taj El-Din added that this cooperation embodies the Egyptian state’s orientation towards strengthening partnership with international companies in the field of the pharmaceutical industry, and the firm belief in the localization of technology and modern manufacturing knowledge in this vital industry. It is an ambitious step towards becoming a leading country in the pharmaceutical industry, ensuring sustainable development and developing the healthcare system, in line with Egypt’s Vision 2030.
He pointed out that Egypt has realized for years that the pharmaceutical industry is not just a traditional industry, but rather a sovereign industry that is directly linked to the health of the Egyptian citizen, national security, and public health. From this standpoint, the state worked to develop a comprehensive strategy aimed at improving local capabilities in the field of drug manufacturing, and providing the appropriate environment to attract international companies with great experience to invest and transfer technology to the Egyptian market.
He noted that through close cooperation between the Egyptian pharmaceutical sector and international pharmaceutical companies, we succeeded in building close foundations for investment and attracting more Egyptian commercial partners to develop effective manufacturing mechanisms, transfer technical knowledge, and localize the joint manufacturing of biopharmaceuticals, in addition to improving the level of efficiency of supply chains and raw materials. Pharmaceuticals and chemicals used in industry.
He explained that cooperation with international companies with manufacturing experience and advanced scientific capabilities represents a major qualitative leap in the path of the Egyptian pharmaceutical industry, pointing out that this cooperation is not limited to merely manufacturing medicine inside Egypt, but rather extends to include the transfer of technology that qualifies Egyptian factories to reach international standards, and the establishment of research and development (R&D) centers inside Egypt to develop innovative medicines using pharmaceutical technologies. Modern.
He added that this cooperation works to expand the partnership in the fields of joint production, ensuring that the ability to produce modern, biological and generic medicines is increased and opening new horizons for export by enhancing the competitiveness of the Egyptian pharmaceutical product in regional and international markets and supporting national competencies through training and transferring expertise through cooperation agreements with international companies that own research and development centers in several countries.
He said that the gains achieved from this cooperation are multiple. To the Egyptian economy, it brings great added value, reduces the import bill, creates direct and indirect job opportunities, and contributes to raising the level of health services.
He added that the rate of industrial growth guarantees the Egyptian citizen the availability of safe and effective medicine at reasonable prices, enhances confidence in the local product, allows entry to a huge market exceeding 110 million consumers, and provides a strategic export gateway to Africa and the Middle East, taking advantage of the geographical location and the Egyptian logistical infrastructure.
He stressed that the localization of the pharmaceutical industry in Egypt is not just an economic goal, but rather an integrated national project that embodies the state’s will to build an advanced industrial base, and strengthen Egypt’s position as a leading regional center in the pharmaceutical industry and pharmaceutical research, to serve the Egyptian citizen, and enhance Egypt’s developmental role in its regional and global environment.
- For more: Follow Khaleejion 24 Arabic, Khaleejion 24 English, Khaleejion 24 Live, and for social media follow us on Facebook and Related
